Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Thyroid Diseases, Thyroid Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Prostatic Neoplasms

Carcinoma, Non-Small-Cell Lung

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Endometrial Neoplasms

Carcinoma, Basal Cell

Endometrial Neoplasms

Carcinoma, Non-Small-Cell Lung

Leukemia, Myeloid, Acute

Carcinoma, Non-Small-Cell Lung

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Renal Cell

Anal Canal Carcinoma, Anus Neoplasms

Ureteral Neoplasms

Breast Neoplasms

Leukemia, Lymphocytic, Chronic, B-Cell

Oropharyngeal Neoplasms

Neoplasm Metastasis

Pancreatic Neoplasms

Anatomic Stage I Breast Cancer AJCC v8

Squamous Cell Carcinoma of Head and Neck

Hematopoietic and Lymphoid System Neoplasm

Head and Neck Neoplasms, Nasopharyngeal Neoplasms, Paranasal Sinus Neoplasms, Salivary Gland Neoplasms

Neoplasms, Small Cell Lung Carcinoma

Prostatic Neoplasms

Breast Neoplasms

Carcinoma, Hepatocellular

Clinical Trials

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

EECRTKI

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

DMU-CH

DIVINE

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

Active Surveillance for the Treatment of Low-Risk Basal Cell Carcinoma in Elderly Patients

Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial

ANVIL

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

AMBASSADOR

RESCUE

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trial

LAP100

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)

Communication Issues in Patient and Provider Discussions of Immunotherapy

EURACAN

TEMPUS Small Cell Lung Cancer OBSERVATIONAL STUDY (Sculptor)

Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Intelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellular Carcinoma